Lantheus Holdings Inc (LNTH)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $6.64B
Last updated: Nov 17, 2026 at 11:06 AM ET
Lantheus Holdings Inc (LNTH) Competitors
The companies most similar to Lantheus Holdings are Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX), Hims Hers Health (HIMS) and Kiniksa Pharmaceuticals (KNSA). Lantheus Holdings trades at 17.9x earnings, against a median of 21.8x for the 10 of these companies with a P/E. By market cap, Lantheus Holdings ranks 7th of the 13 companies on this page; United Therapeutics (UTHR) is the largest at $25.18B.
Peer Comparison
LNTH's ROIC of 14.8% is above the peer median of 5.7%, and its revenue growth of 1.5% is below the median of 12.4%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Lantheus Holdings (LNTH) | $6.64B | 17.9x | 4.5x | 17.3% | 14.8% | 1.5% | 0.00% |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $7.45B | 21.4x | 2.2x | 4.2% | 11.6% | 10.0% | 0.00% |
| Hims Hers Health Inc (HIMS) | $4.62B | N/A | 1.5x | -6.7% | -11.1% | 48.6% | 0.00% |
| Kiniksa Pharmaceuticals Ltd (KNSA) | $7.57B | 72.5x | 7.8x | 11.6% | N/A | 58.1% | 0.00% |
| Elanco Animal Health (ELAN) | $13.39B | 23.2x | 2.6x | -2.9% | 1.6% | 11.3% | 0.00% |
| Bausch Health Companies Inc (BHC) | $3.13B | 1.7x | 0.3x | -7.6% | 6.3% | 9.7% | 0.00% |
| Neurocrine Biosciences Inc (NBIX) | $16.94B | 18.4x | 4.5x | 19.0% | N/A | 41.2% | 0.00% |
| Indivior PLC Ordinary Shares (INDV) | $4.28B | 6.6x | 2.4x | 32.8% | 109.0% | 13.4% | 0.00% |
| Prestige Brand Holdings Inc (PBH) | $2.19B | 10.7x | 2.0x | 13.3% | 5.0% | 22.7% | 0.00% |
| HUTCHMED DRC (HCM) | $2.59B | N/A | 4.7x | 3.3% | -2.4% | 0.2% | 0.00% |
| Xeris Pharmaceuticals Inc (XERS) | $3.04B | 139.2x | 8.2x | -1.8% | 15.5% | 44.2% | 0.00% |
| Dr. Reddy’s Laboratories Ltd ADR (RDY) | $12.29B | 39.6x | 3.5x | 8.5% | 5.7% | -1.5% | 0.44% |
| United Therapeutics Corporation (UTHR) | $25.18B | 22.2x | 7.9x | 38.6% | N/A | 4.1% | 0.00% |
| Peer median | $6.04B | 21.8x | 3.0x | 6.3% | 5.7% | 12.4% | 0.00% |
Similar Companies
These are the 12 companies most similar to Lantheus Holdings, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Drug Manufacturers - Specialty & Generic.
| Company | About | Peers |
|---|---|---|
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets and distributes generic and specialty pharmaceutical products for various dosage forms... | AMRX competitors |
| Hims Hers Health Inc (HIMS) | Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers with licensed healthcare professionals. | HIMS competitors |
| Kiniksa Pharmaceuticals Ltd (KNSA) | Kiniksa Pharmaceuticals Ltd. (KNSA) is an innovative biopharmaceutical company focused on developing breakthrough therapies to address pressing unmet medical... | KNSA competitors |
| Elanco Animal Health (ELAN) | Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures and markets products for pets and farm animals. | ELAN competitors |
| Bausch Health Companies Inc (BHC) | Bausch Health Companies Inc. develops, manufactures and markets a range of pharmaceutical... | BHC competitors |
| Neurocrine Biosciences Inc (NBIX) | Neurocrine Biosciences, Inc., a biopharmaceutical company, discovers, develops, and markets pharmaceutical products for the treatment of neurological... | NBIX competitors |
| Indivior PLC Ordinary Shares (INDV) | Indivior PLC, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence... | |
| Prestige Brand Holdings Inc (PBH) | Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States... | PBH competitors |
| HUTCHMED DRC (HCM) | HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. | |
| Xeris Pharmaceuticals Inc (XERS) | Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and markets ready-to-use injectable and infusible drug formulations. | XERS competitors |
| Dr. Reddy’s Laboratories Ltd ADR (RDY) | Dr. Reddy's Laboratories Limited is a globally integrated pharmaceutical company. The company is headquartered in Hyderabad, India. | RDY competitors |
| United Therapeutics Corporation (UTHR) | United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs... | UTHR competitors |
Frequently Asked Questions About LNTH
Who are Lantheus Holdings' main competitors?
The companies most similar to Lantheus Holdings include Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX), Hims Hers Health (HIMS), Kiniksa Pharmaceuticals (KNSA), Elanco Animal Health (ELAN) and Bausch Health Companies (BHC), listed from the closest match.
Who is Lantheus Holdings' biggest competitor?
United Therapeutics (UTHR) is the largest of the similar companies at $25.18B; Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is the closest match by business profile, size, sector and industry.
How does LNTH stock compare with its competitors?
LNTH's P/E is 17.9x against a peer median of 21.8x; its P/S is 4.5x against a peer median of 3.0x; its net margin is 17.3% against a peer median of 6.3%.
Which of Lantheus Holdings' competitors pays a higher dividend?
Lantheus Holdings pays no dividend. Dr. Reddy’s Laboratories Ltd ADR (RDY) has a higher forward dividend yield; Dr. Reddy’s Laboratories Ltd ADR (RDY) has the highest at 0.44%.
Is Lantheus Holdings bigger than its competitors?
No. Lantheus Holdings is 7th by market cap among the 13 companies on this page; the largest is United Therapeutics (UTHR) at $25.18B.
LNTH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts